Mutch, David - Siteman Cancer Center

David Mutch, MD

Gynecologic Oncology, Surgeon

Primary Academic Title

Professor, Vice Chair of Obstetrics and Gynecology, Washington University School of Medicine

Clinical Expertise

As a member of our ovarian, cervical and endometrial cancer specialist teams, Dr. Mutch cares for patients diagnosed with these cancers through treatment and recovery.

https://siteman.wustl.edu/research/endometrial-cancer-spore/

Research Interest

Cytokine activity against tumor cell mechanism of action; molecular genetics of endometrial and ovarian cancers; and RER mutations, LOH, cloning areas of loss on 10q and 1p.

Education

1980: MD, Washington University, St. Louis

Training

1980 - 1984: Resident, obstetrics and gynecology, Washington University, St. Louis
1984 - 1987: Fellow, gynecologic oncology, Duke University, Durham, N.C.

Board Certification

1988: American Board of Obstetrics and Gynecology, Obstetrics and Gynecology
1989: American Board of Obstetrics and Gynecology, Gynecologic Oncology

Selected Research Publications

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

Mutch D, Voulgari A, Chen XM, [...] Yan Y
Cancer 2024

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.

Patel SP, Othus M, Chae YK, [...] Mutch D, [...] Kurzrock R
Clin Cancer Res 2024

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.

Abu-Rustum NR, Yashar CM, Arend R, [...] Mutch D, [...] Espinosa S
J Natl Compr Canc Netw 2023

Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.

Hagemann IS, Deng W, Zaino RJ, [...] Mutch DG
Gynecol Oncol 2023

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.

Compadre AJ, van Biljon LN, Valentine MC, [...] Mutch DG, [...] Mullen MM
Clin Cancer Res 2023

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

Abu-Rustum N, Yashar C, Arend R, [...] Mutch D, [...] Aggarwal S
J Natl Compr Canc Netw 2023

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.

You B, Purdy C, Copeland LJ, [...] Mutch D, [...] Burger RA
J Clin Oncol 2022

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Thiel KW, Devor EJ, Filiaci VL, Mutch D, [...] Leslie KK
J Clin Oncol 2022

Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).

Donovan HS, Sereika SM, Wenzel LB, [...] Mutch DG, [...] Ward SE
J Clin Oncol 2022

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.

Powell MA, Filiaci VL, Hensley ML, [...] Mutch DG, [...] Miller DS
J Clin Oncol 2022

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.

Abu-Rustum NR, Yashar CM, Bradley K, [...] Mutch D, [...] Motter AD
J Natl Compr Canc Netw 2021

The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer.

Olawaiye AB, Baker TP, Washington MK, Mutch DG
CA Cancer J Clin 2021